MX2015002934A - Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad. - Google Patents

Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad.

Info

Publication number
MX2015002934A
MX2015002934A MX2015002934A MX2015002934A MX2015002934A MX 2015002934 A MX2015002934 A MX 2015002934A MX 2015002934 A MX2015002934 A MX 2015002934A MX 2015002934 A MX2015002934 A MX 2015002934A MX 2015002934 A MX2015002934 A MX 2015002934A
Authority
MX
Mexico
Prior art keywords
methods
treatment
weight loss
obesity
administering rifaximin
Prior art date
Application number
MX2015002934A
Other languages
English (en)
Inventor
Charles W Randall
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2015002934A publication Critical patent/MX2015002934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Se proveen métodos de reducción de peso en un sujeto, en donde los métodos comprenden administrar una composición que comprende una cantidad eficaz de rifaximina a un sujeto que necesita tratamiento para pérdida de peso. En algunas modalidades, el sujeto se considera obeso (BMI > 30).
MX2015002934A 2012-09-13 2013-09-13 Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad. MX2015002934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700866P 2012-09-13 2012-09-13
PCT/US2013/059589 WO2014043432A1 (en) 2012-09-13 2013-09-13 Methods of administering rifaximin for weight loss and treatment of obesity

Publications (1)

Publication Number Publication Date
MX2015002934A true MX2015002934A (es) 2015-10-29

Family

ID=50278698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002934A MX2015002934A (es) 2012-09-13 2013-09-13 Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad.

Country Status (11)

Country Link
US (1) US20150164866A1 (es)
EP (1) EP2894983A4 (es)
JP (1) JP2015528506A (es)
CN (1) CN104780763A (es)
AU (1) AU2013315382A1 (es)
CA (1) CA2886269A1 (es)
EA (1) EA201590522A1 (es)
HK (1) HK1212554A1 (es)
MX (1) MX2015002934A (es)
TN (1) TN2015000048A1 (es)
WO (1) WO2014043432A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6671360B2 (ja) * 2014-06-30 2020-03-25 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法
EA039096B1 (ru) * 2014-08-11 2021-12-03 Саликс Фармасьютикалз, ИНК. Способы лечения заболевания кишечника (срк)
CN105811953B (zh) * 2016-04-21 2019-05-28 山东师范大学 二碘化铅薄膜在亚皮秒全光磁开关中的应用
WO2020198136A1 (en) * 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0834730A (ja) * 1994-07-26 1996-02-06 Teijin Ltd アミリン凝集阻害剤
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
US20090305993A1 (en) * 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
AU2009285725A1 (en) * 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
US20130230498A1 (en) * 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
SG10201507035UA (en) * 2010-06-03 2015-10-29 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20150164866A1 (en) 2015-06-18
EP2894983A1 (en) 2015-07-22
CN104780763A (zh) 2015-07-15
CA2886269A1 (en) 2014-03-20
WO2014043432A8 (en) 2015-01-22
EA201590522A1 (ru) 2015-06-30
HK1212554A1 (zh) 2016-06-17
JP2015528506A (ja) 2015-09-28
WO2014043432A1 (en) 2014-03-20
AU2013315382A1 (en) 2015-03-05
TN2015000048A1 (en) 2016-06-29
EP2894983A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
IN2015DN01156A (es)
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12015501291B1 (en) Functionalized exendin-4 derivatives
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
TN2012000414A1 (en) Forms of rifaximin and uses thereof
GB2492305A (en) Polymers of benzodithiophene and their use as organic semiconductors
NZ588954A (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MY160241A (en) 5-alkynyl-pyrimidines
MX2022001251A (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
MX365650B (es) Composiciones de amantadina y metodos para su uso.
IN2014DN06104A (es)
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MX342947B (es) Tratamiento de diabetes tipo 2.
TN2015000048A1 (en) Methods of administering rifaximin for weight loss and treatment of obesity
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
NZ720788A (en) Eczema treatment
UA64712U (ru) Дуга-пластина для коррекции воронкообразной деформации грудной клетки у детей
WO2012031754A3 (de) Vorrichtung zur stabilisierung eines körpers